Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2030

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Datopotamab Deruxtecan (Dato-DXd)

Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.

DRUG

Durvalumab

Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.

Trial Locations (1)

Barts Cancer Institute, Centre of Experimental Cancer Medicine, London